{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:12:34Z","timestamp":1790993554107,"version":"4.1.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Vitiligo and alopecia areata are common, disfiguring skin diseases. Treatment options are limited and include nontargeted approaches, such as corticosteroids, topical calcineurin inhibitors, narrow band ultraviolet B phototherapy, and other immune-modifying agents. The purpose of this article is to review shared, novel mechanisms between vitiligo and alopecia areata, as well as discuss how they inform the development of future targeted treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      Vitiligo and alopecia areata are both autoimmune diseases, and striking similarities in pathogenesis have been identified at the level of both the innate and adaptive immune system. Increased reactive oxygen species and high cellular stress level have been suggested as the initiating trigger of the innate immune system in both diseases, and genome-wide association studies have implicated risk alleles that influence both innate and adaptive immunity. Most importantly, mechanistic studies in mouse models of vitiligo and alopecia areata have specifically implicated an interferon (IFN)\u03b3-driven immune response, including IFN\u03b3, IFN\u03b3-induced chemokines, and cytotoxic CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells as the main drivers of disease pathogenesis. These recent discoveries may reveal an effective strategy to develop new treatments, and several proof-of-concept clinical studies support this hypothesis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The identification of IFN\u03b3-driven immune signaling pathways has enabled discoveries of potential new treatments for vitiligo and alopecia areata, and supports initiation of larger clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000000375","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T11:44:00Z","timestamp":1463485440000},"page":"463-469","source":"Crossref","is-referenced-by-count":85,"title":["Understanding autoimmunity of vitiligo and alopecia areata"],"prefix":"10.1097","volume":"28","author":[{"given":"Jillian F.","family":"Rork","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Rashighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"R2-20230918","article-title":"Evidence-Based Management of vitiligo: summary of a Cochrane systematic review","author":"Whitton","year":"2015","journal-title":"Br J Dermatol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaad.2009.10.032","article-title":"Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40257-014-0086-4","article-title":"Alopecia areata: an evidence-based treatment update","volume":"15","author":"Hordinsky","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4 T cells: fates, functions, and faults","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaad.2015.08.063","article-title":"Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study","volume":"74","author":"Gill","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ng.2272","article-title":"Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo","volume":"44","author":"Jin","year":"2012","journal-title":"Nat Genet"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/jid.2011.321","article-title":"Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis","volume":"132","author":"Spritz","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/imr.12369","article-title":"Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo","volume":"269","author":"Harris","year":"2016","journal-title":"Immunol Rev"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/pcmr.12402","article-title":"Use of permanent hair dyes and risk of vitiligo in women","volume":"28","author":"Wu","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/pcmr.12208","article-title":"Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress","volume":"27","author":"Mosenson","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/jid.2012.181","article-title":"Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8","volume":"132","author":"Toosi","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/jid.2011.16","article-title":"Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy","volume":"131","author":"van den Boorn","year":"2011","journal-title":"J Invest Dermatol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"ra128","DOI":"10.1126\/scitranslmed.3005127","article-title":"Mutant HSP70 reverses autoimmune depigmentation in vitiligo","volume":"5","author":"Mosenson","year":"2013","journal-title":"Sci Transl Med"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2015.09.003","article-title":"Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity?","volume":"81","author":"Xie","year":"2016","journal-title":"J Dermatol Sci"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/jidsymp.2015.8","article-title":"Oxidative stress-induced chemokine production mediates CD8(+) T cell skin trafficking in vitiligo","volume":"17","author":"Li","year":"2015","journal-title":"J Investig Dermatol Symp Proc"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"223ra223","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R20-20230918","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in vitiligo patients and CXCL10 as a potential clinical marker for vitiligo","author":"Wang","year":"2016","journal-title":"Br J Dermatol"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjd.12013","article-title":"The distribution pattern of segmental vitiligo: clues for somatic mosaicism","volume":"168","author":"van Geel","year":"2013","journal-title":"Br J Dermatol"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","article-title":"The autoimmune basis of alopecia areata: a comprehensive review","volume":"14","author":"Islam","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/exd.12489","article-title":"The role of cytokines and chemokines in the T-cell-mediated autoimmune process in alopecia areata","volume":"23","author":"Ito","year":"2014","journal-title":"Exp Dermatol"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/exd.12209","article-title":"What causes alopecia areata?","volume":"22","author":"McElwee","year":"2013","journal-title":"Exp Dermatol"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1038\/ncomms6966","article-title":"Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci","volume":"6","author":"Betz","year":"2015","journal-title":"Nat Commun"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/JID.2015.402","article-title":"Functional interpretation of genome-wide association study evidence in alopecia areata","volume":"136","author":"Petukhova","year":"2016","journal-title":"J Invest Dermatol"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/jid.2012.17","article-title":"Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse","volume":"132","author":"McPhee","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Suarez-Farinas","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/exd.12264","article-title":"Vitiligo and alopecia areata: apples and oranges?","volume":"22","author":"Harris","year":"2013","journal-title":"Exp Dermatol"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40257-013-0036-6","article-title":"Oxidative stress in alopecia areata: a case-control study","volume":"15","author":"Bakry","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"R32-20230918","first-page":"43","article-title":"Oxidative stress and alopecia areata","volume":"8","author":"Prie","year":"2015","journal-title":"J Med Life"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.coi.2013.10.010","article-title":"Innate immune mechanisms in vitiligo: danger from within","volume":"25","author":"Richmond","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"R34-20230918","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/ced.12556","article-title":"Investigation of oxidative stress in patients with alopecia areata and its relationship with disease severity, duration, recurrence and pattern","volume":"40","author":"Yenin","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"R35-20230918","first-page":"343","article-title":"Interfering with the IFN-gamma\/CXCL10 pathway to develop new targeted treatments for vitiligo","volume":"3","author":"Rashighi","year":"2015","journal-title":"Ann Transl Med"},{"key":"R36-20230918","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R37-20230918","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R38-20230918","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"key":"R39-20230918","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.23871","article-title":"Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia","volume":"90","author":"Pieri","year":"2015","journal-title":"Am J Hematol"},{"key":"R40-20230918","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R41-20230918","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R42-20230918","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/jid.2011.41","article-title":"Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita","volume":"131","author":"Zhao","year":"2011","journal-title":"J Invest Dermatol"},{"key":"R43-20230918","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-3-7","article-title":"Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo","volume":"3","author":"Noel","year":"2004","journal-title":"Lipids Health Dis"},{"key":"R44-20230918","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/jid.2014.529","article-title":"Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo","volume":"135","author":"Agarwal","year":"2015","journal-title":"J Invest Dermatol"},{"key":"R47-20230918","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaad.2014.11.006","article-title":"Treatment of alopecia areata with simvastatin\/ezetimibe","volume":"72","author":"Lattouf","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R48-20230918","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2015.11.001","article-title":"Extensive alopecia areata is reversed by IL-12\/IL-23p40 cytokine antagonism","volume":"137","author":"Guttman-Yassky","year":"2016","journal-title":"J Allergy Clin Immunol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201608000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T22:12:28Z","timestamp":1694988748000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201608000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000375","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}